ArticleVeterinary research communications2023
Peptide hydrolysate from fish skin collagen to prevent and treat Aeromonas hydrophila infection in Oreochromis niloticus.
Article in Veterinary research communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 8 citations in OpenAlex.
- Criteria for the Characterization of Seafood Byproducts to Allow Tracing Their Geographic Origin.Foods (Basel, Switzerland) · 2026Review
- Fish By-Products Utilization in Food and Health: Extraction Technologies, Bioactive, and Sustainability Challenges.Food science & nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aquaculture with an intensive system can both increase production and the disease risk. The use of antibiotics to reduce pathogens has bacterial resistance consequence. Peptides have rapidly gained more attention due to their antibacterial and immunomodulatory properties important to combat pathogens. This study aimed to determine the effectiveness of peptide hydrolysate against Aeromonas hydrophila in vitro and in vivo in Nile tilapia. The peptides obtained from fish skin collagen of tilapia, milkfish, and catfish were applied in different doses. Protein content and hydrolysis degree of the peptide were also measured. The peptides were tested in vitro using A. hydrophila. For in vivo test, The peptides and positive control treatments used A. hydrophila bacteria, while negative control treatment used a phosphate buffer saline (PBS). The results showed that all three peptide hydrolysates had similar protein content. The highest hydrolysis degree was shown by milkfish collagen hydrolysate. In vitro assay revealed that 12.5% milkfish skin collagen obtained the highest antibacterial activity. In vivo assay showed that the phagocytic activity, respiratory burst, and lysozyme activity was higher in preventive control than therapy, positive control, or negative control treatments. The growth and survival rate in preventive control was also better than positive control or therapy treatment. This study concludes that the peptide hydrolysate can inhibit the growth of A. hydrophila. Peptide hydrolysate from milkfish skin collagen at 12.5% dose was more effective in preventing the A. hydrophila infection, regarding the immune response, growth, and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.